These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12429461)

  • 1. Physical property of troglitazone, an equal mixture of four stereoisomers.
    Suzuki N; Kasahara K; Hasegawa H; Kawasaki T
    Int J Pharm; 2002 Nov; 248(1-2):71-80. PubMed ID: 12429461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct chiral separation of troglitazone stereoisomers using reversed-phase high-performance liquid chromatography.
    Suzuki N; Takemura A; Miyamoto A; Yoshioka T; Tsutsumi S; Kawasaki T
    J Pharm Biomed Anal; 2002 Oct; 30(3):823-36. PubMed ID: 12367708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid-state variation of troglitazone drug substance by using a different recrystallization method.
    Suzuki N; Kasahara K; Watanabe Y; Kinoshita S; Hasegawa H; Kawasaki T
    Drug Dev Ind Pharm; 2003 Aug; 29(7):805-12. PubMed ID: 12906338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of solid state form of troglitazone by solid state NMR spectroscopy.
    Suzuki N; Kawasaki T
    J Pharm Biomed Anal; 2005 Feb; 37(1):177-81. PubMed ID: 15664759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of solid dispersions on a molecular level by the Raman mapping technique.
    Furuyama N; Hasegawa S; Hamaura T; Yada S; Nakagami H; Yonemochi E; Terada K
    Int J Pharm; 2008 Sep; 361(1-2):12-8. PubMed ID: 18584979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do amorphous troglitazones prepared from two diastereomer-pairs have the same molecular mobility and crystallization rate at the surface?
    Furuyama N; Hasegawa S; Yada S; Hamaura T; Wakiyama N; Yonemochi E; Terada K; Buckton G
    Chem Pharm Bull (Tokyo); 2011; 59(12):1452-7. PubMed ID: 22130365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicochemical and crystal structure analyses of the antidiabetic agent troglitazone.
    Kobayashi K; Fukuhara H; Hata T; Sekine A; Uekusa H; Ohashi Y
    Chem Pharm Bull (Tokyo); 2003 Jul; 51(7):807-14. PubMed ID: 12843587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structure of an antidiabetic agent, (+/-)-5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]-2,4-dioxothiazollidine, troglitazone dihydrate.
    Kobayashi K; Fukuhara H; Hata T
    Anal Sci; 2001 Mar; 17(3):467-8. PubMed ID: 11990631
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetic stereoselectivity of troglitazone, an antidiabetic agent, in the KK mouse.
    Izumi T; Enomoto S; Hoshiyama K; Sasahara K; Sugiyama Y
    Biopharm Drug Dispos; 1997 May; 18(4):305-24. PubMed ID: 9158879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Method development and validation for the HPLC potency assay of troglitazone tablets.
    Lambropoulos J; Bergholdt AB
    J Pharm Biomed Anal; 2000 Dec; 24(2):251-8. PubMed ID: 11130204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of physical properties of troglitazone crystal on the molecular interaction with PVP during heating.
    Hasegawa S; Furuyama N; Yada S; Hamaura T; Kusai A; Yonemochi E; Terada K
    Int J Pharm; 2007 May; 336(1):82-9. PubMed ID: 17178201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of protein binding of troglitazone stereoisomers by fluorometric titration.
    Izumi T; Hoshiyama K; Enomoto S; Sasahara K; Sugiyama Y
    Biopharm Drug Dispos; 1997 Apr; 18(3):241-57. PubMed ID: 9113346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of water content in physical mixture and heating temperature on crystallinity of troglitazone-PVP K30 solid dispersions prepared by closed melting method.
    Hasegawa S; Hamaura T; Furuyama N; Kusai A; Yonemochi E; Terada K
    Int J Pharm; 2005 Sep; 302(1-2):103-12. PubMed ID: 16102926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of troglitazone stereoisomers in rat plasma using semi-micro HPLC with electrochemical detection.
    Suzuki N; Miyashita N; Kotani A; Kusu F; Kawasaki T
    J Pharm Biomed Anal; 2005 Jun; 38(1):155-61. PubMed ID: 15907634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uniformity and physical states of troglitazone in solid dispersions determined by electron probe microanalysis and microthermal analysis.
    Hasegawa S; Hamaura T; Furuyama N; Horikawa S; Kusai A; Yonemochi E; Terada K
    Int J Pharm; 2004 Aug; 280(1-2):39-46. PubMed ID: 15265545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Troglitazone, an euglycemic antidiabetic drug.
    Vyas K; Sivalakshmidevi A; Prabhakar C; Reddy GO
    Acta Crystallogr C; 1999 Mar; 55 ( Pt 3)():411-3. PubMed ID: 10220869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural studies on the impurities of troglitazone.
    Moses Babu J; Nageshwar D; Ravindra Kumar Y; Prabhakar C; Sarma MR; Om Reddy G; Vyas K
    J Pharm Biomed Anal; 2003 Feb; 31(2):271-81. PubMed ID: 12609666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photooxidation of troglitazone, a new antidiabetic drug.
    Fu Y; Sheu C; Fujita T; Foote CS
    Photochem Photobiol; 1996 May; 63(5):615-20. PubMed ID: 8628753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse.
    Beales PE; Liddi R; Giorgini AE; Signore A; Procaccini E; Batchelor K; Pozzilli P
    Eur J Pharmacol; 1998 Sep; 357(2-3):221-5. PubMed ID: 9797040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
    Johnson MD; Campbell LK; Campbell RK
    Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.